NCOA3 and gastric cancer: The results indicated that AIB1 amplification might be served as a predictor of poor survival in gastric cancer (HR = 1.85; 95% CI = 1.08–3.18; P = 0.03) as an independently variable with respect to gender, age, differentiation and TNM stage (Table 3).